Abstract:We divided glioma patients into the high‐ and low‐glioma stem cell (GSC) groups. GSC‐enriched patients had higher chemo‐radiotherapy resistance and worse prognosis than low‐GSC patients. Tumor treating field (TTF) therapy can effectively inhibit malignant biological characteristics of GSC‐enriched gliomas, including mitosis, angiogenesis, migration and invasion potential. TTF also could break the original DNA balance in GSC‐enriched gliomas. Taken together, TTF is a promising therapeutic approach for GSC‐enriched glioma patients. Introduction Glioma stem cells (GSCs) play an important role in glioma recurrence and chemo‐radiotherapy (CRT) resistance. Currently, there is a lack of efficient treatment approaches targeting GSCs. This study aimed to explore the potential personalized treatment of patients with GSC‐enriched gliomas. Methods Single‐cell RNA sequencing (scRNA‐seq) was used to identify the GSC‐related genes. Then, machine learning methods were applied for clustering and validation. The least absolute shrinkage and selection operator (LASSO) and COX regression were used to construct the risk scores. Survival analysis was performed. Additionally, the incidence of chemo‐radiotherapy resistance, immunotherapy status, and tumor treating field (TTF) therapy response were evaluated in high‐ and low‐risk scores groups. Results Two GSC clusters exhibited significantly different stemness indices, immune microenvironments, and genomic alterations. Based on GSC clusters, 11‐gene GSC risk scores were constructed, which exhibited a high predictive value for prognosis. In terms of therapy, patients with high GSC risk scores had a higher risk of resistance to chemotherapy. TTF therapy can comprehensively inhibit the malignant biological characteristics of the high GSC‐risk‐score gliomas. Conclusion Our study constructed a GSC signature consisting of 11 GSC‐specific genes and identified its prognostic value in gliomas. TTF is a promising therapeutic approach for patients with GSC‐enriched glioma.

Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment